Evidence-based, cost-effective risk stratification and management after myocardial infarction

Archives of Internal Medicine

Volumn 157, Issue 3, 1997, Pages 273-280

  Deedwania, Prakash C ^a   Amsterdam, Ezra A ^b   Vagelos, Randall H ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; BEHAVIOR MODIFICATION; COST EFFECTIVENESS ANALYSIS; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT PLANNING;

EID: 0031022773     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.3.273     Document Type: Article

References (47)

1. American Heart Association. Heart and Stroke Facts: 1995 Statistical Supplement. Dallas, Tex: American Heart Association; 1995.
2. Deedwania PC, Carbajal EV. Secondary prevention after myocardial infarction: too many choices, which ones work? Arch Intern Med. 1993;153: 285-287.
3. Deedwania PC. Clinical perspectives on primary and secondary prevention of coronary atherosclerosis. Med Clin North Am. 1995;79:973-998.
4. Pilote L, Miller DP, Califf RM, et al. Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med. 1996;335:1198-1205.
5. Epstein SE, Palmari ST, Patterson RE. Evaluation of patients after acute myocardial infarction: indications for cardiac catheterization and surgical intervention. N Engl J Med. 1982;307: 1487-1492.
6. Nicod P, Gilpin E, Dittrich H, et al. Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction. Am J Cardiol. 1988;61:1165-1171.
7. DeBusk RF, Glomqvist CG, Kouchoukos NT, et al. Identification and treatment of low-risk patients after acute myocardial infarction and coronary-artery bypass graft surgery. N Engl J Med. 1986;314:161-166.
8. Goldschlager N. Management of the postmyocardial infarction patient. In: Parmley WW, Chatterjee K, eds. Cardiology. Philadelphia, Pa: JB Lippincott; 1990:chap 7.
9. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med. 1983;309:331-336.
10. Yusuf S, Lessem J, Jha P, et al. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. J Hypertens. 1993;11(suppl 4): S61-S73.
11. Sami M, Draemer H, DeBusk RF. The prognostic significance of serial exercise testing after myocardial infarction. Circulation. 1979;60:1238-1246.
12. Theroux P, Waters DD, Halphen C, et al. Prognostic value of exercise testing soon after myocardial infarction. N Engl J Med. 1979;301:341-345.
13. Krone RJ. The role of risk stratification in the early management of a myocardial infarction. Ann Intern Med. 1992;116:223-237.
14. Bigger JT Jr, Fleiss JL, Kleiger R, et al. The relationship among ventricular arrhythmias, left ventricular dysfunction, and mortality in the two years after myocardial infarction. Circulation. 1984;69: 250-258.
15. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med. 1989;320:618-627.
16. Moss AJ, Benhorin J. Prognosis and management after a first myocardial infarction. N Engl J Med. 1990;322:743-753.
17. Task Force of Practice Guidelines. ACC-AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol. 1996; 28:1328-1428.
18. Kao W, Khaja F, Goldstein S, Gheglinade M. Cardiac event rate after non-Q-wave acute myocardial infarction and the significance of its anterior location. Am J Cardiol. 1989;64:1236-1242.
19. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ. 1988;296:320-331.
20. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction, I: marketed results. JAMA. 1982;247:1707-1714.
21. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992; 327:669-677.
22. The Acute Infarction Ramipril Efficacy Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
23. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995; 332:80-85.
24. Ball SG, Hall AS. What to expect from ACE inhibitors after myocardial infarction. Br Heart J. 1994;72(suppl 3):S70-S74.
25. Turpie AG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989;320: 352-357.
26. Siegel D, Grady D, Browner WS, et al. Risk factor modification after myocardial infarction. Ann Intern Med. 1988;109:213-218.
27. Superko HR, Krauss RM. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation. 1994;90:1056-1069.
28. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
29. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
30. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322:1700-1707.
31. Amsterdam EA, Hyson D, Kappagoda CT, et al. Nonpharmacologic therapy for coronary artery atherosclerosis: results of primary and secondary prevention trials. Am Heart J. 1994;128: 1344-1352.
32. Ronnevik PK, Gundersen T, Abrahamsen AM. Effect of smoking habits and timolol treatment on mortality and reinfarction in patients surviving acute myocardial infarction. Br Heart J. 1985;54:134-139.
33. Rosenberg L, Kaufman DW, Helmrich SP, et al. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med. 1985;313:1511-1514.
34. Ockene JK. Smoking intervention: a behavioral, educational, and pharmacologic perspective. In: Ockene IS, Ockene JK, eds. Prevention of Coronary Heart Disease. Boston, Mass: Little Brown & Co Inc; 1992:201-230.
35. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med. 1995;333:1196-1203.
36. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
37. The Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
38. Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol. 1993;22:933-940.
39. Kannel WB, Sorlie P, Castelli WP, McGee D. Blood pressure and survival after myocardial infarction: the Framingham Study. Am J Cardiol. 1980;45: 326-330.
40. The Coronary Drug Project Research Group. Blood pressure in survivors of myocardial infarction. J Am Coll Cardiol. 1984;4:1135-1147.
41. Herlitz J, Karlson BW, Richter A, et al. Prognosis in hypertensives with acute myocardial infarction. J Hypertens. 1992;10:1265-1271.
42. Connolly DC, Elveback OR, Oxman HA. Coronary heart disease in residents of Rochester, Minnesota, 1950-1975, III: effective hypertension and its treatment on survival of patients with coronary artery disease. Mayo Clin Proc. 1983;58:249-254.
43. Langford HG, Stamler J, Wassertheil-Smoller S, Prineas RJ. All-cause mortality in the hypertension detection and follow-up program: findings for the whole cohort and for the persons with less severe hypertension, with and without other traits related to risk of mortality. Prog Cardiovasc Dis. 1986;29(suppl 1):29-54.
44. Laslett L, Paumer L, Amsterdam EA. Exercise training in coronary artery disease. Cardiol Clin. 1987; 5:211-225.
45. Haskell WL. Sedentary lifestyle is a risk factor for coronary heart disease. In: Pearson TA, Criqui MH, Leupker RV, et al, eds. Primer in Preventive Cardiology. Dallas, Tex: American Heart Association; 1994:173-187.
46. Ghilarducci LE, Holly RG, Amsterdam EA, Atkinson RL. Effects of cardiac stress during a very-low-calorie diet and exercise program in obese women. Am J Clin Nutr. 1989;50:1324-1327.
47. Oldridge N, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction: combined experience of randomized clinical trials. JAMA. 1988;260:945-950.